Physician profile
Sarit Jane Itenberg
NPI 1508153313
$17,934.02
in general payments reported to CMS, 2019-2025
35 companies · $647 in 2025
The $647 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,375 · 2020: $2,770 · 2021: $3,994 · 2022: $4,759 · 2023: $2,746 · 2024: $642 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,791 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,790.59 |
| Education | $245.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $2,925.03 | 2019-2025 | Adbry, Anzupgo |
| Abbvie INC. | $2,859.38 | 2019-2025 | |
| Amgen INC. | $1,666.21 | 2019-2023 | Otezla |
| Janssen Biotech, INC. | $1,553.08 | 2019-2023 | Tremfya, Simponi, Stelara |
| Novartis Pharmaceuticals Corporation | $1,285.50 | 2019-2024 | |
| Pfizer INC. | $1,228.01 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $771.65 | 2020-2021 | |
| Ucb, INC. | $739.43 | 2019-2024 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $632.78 | 2019-2025 | Dupixent |
| Incyte Corporation | $603.11 | 2021-2023 | Opzelura |
| Genzyme Corporation | $595.29 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $585.18 | 2019-2024 | Absorica Ld, Winlevi |
| Revance Therapeutics, INC. | $508.21 | 2024-2025 | Daxxify |
| E.R. Squibb & Sons, L.L.C. | $391.38 | 2022-2023 | Sotyktu |
| Dermavant Sciences, INC. | $268.80 | 2022-2024 | Vtama |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $224.24 | 2019-2023 | Taltz |
| Galderma Laboratories, L.P. | $174.89 | 2019-2022 | |
| Celgene Corporation | $125.98 | 2019 | |
| Strata Skin Sciences, INC. | $122.02 | 2020-2024 | Xtrac |
| Lexicon Pharmaceuticals, INC. | $91.51 | 2025 | |
| Dermira, INC. | $81.21 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $67.65 | 2019-2021 | |
| Almirall LLC | $50.23 | 2019-2020 | |
| Organon LLC | $50.10 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $45.06 | 2022-2024 | Jublia |
| Merz North America, INC. | $40.75 | 2019 | |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $39.85 | 2019 | |
| Allergan, INC. | $35.95 | 2019 | |
| Mission Pharmacal Company | $33.73 | 2021 | |
| Biofrontera INC. | $31.88 | 2021-2022 | |
| Dusa Pharmaceuticals, INC. | $31.46 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.01 | 2022 | |
| Journey Medical Corporation | $18.04 | 2024 | |
| Arcutis Biotherapeutics, INC. | $13.62 | 2023 | |
| Merck Sharp & Dohme LLC | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarit Itenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.